The Gender Pain Gap
Migraine is the third most prevalent illness in the world and disproportionately affects women — at roughly three times the rate of men. It is not simply a bad headache. It is a complex neurological condition with documented sex-specific triggers, including estrogen fluctuations across the menstrual cycle, pregnancy, postpartum, perimenopause, and the use of hormonal contraception or hormone therapy.
Despite this prevalence, migraine remains chronically underfunded relative to its disease burden. The gender pain gap — the well-documented tendency of clinicians to underestimate, dismiss, or psychologize pain in women — means that women wait longer for diagnosis, are less likely to receive appropriate treatment, and are more likely to be told their symptoms have no organic basis.
Hormonal Complexity
Menstrual migraine, which affects roughly half of women who experience migraine, is triggered by the decline in estrogen in the days before menstruation. Understanding and treating this pattern requires clinical fluency with hormonal biology that many providers lack. The same hormonal dynamics that make migraine more prevalent in women across the reproductive years also make management more complex — and more dependent on coordinated care between neurology and gynecology that rarely exists in practice.
Perimenopause represents a particularly vulnerable window. As estrogen levels fluctuate dramatically during the menopause transition, migraine frequency and severity often increase. Many women in this stage receive neither adequate neurological care nor recognition that their symptoms are hormonally mediated.
Chronic Pain More Broadly
Migraine sits within a broader landscape of chronic pain conditions that disproportionately affect women — fibromyalgia, temporomandibular disorders, interstitial cystitis, and others. Across this landscape, women are more likely to have their pain attributed to anxiety, depression, or stress, and less likely to receive specialist referral or evidence-based pharmacological treatment. This is not a perception problem. It is documented in the clinical literature and has measurable consequences for health outcomes.
What We Track
We monitor NIH funding for sex-specific pain research, FDA approvals for migraine treatments with sex-disaggregated trial data, and policy developments affecting access to specialist neurological and pain management care for women.
